ANIXA BIOSCIENCES, INC. Anixa Biosciences, Inc. announced that its partner, Cleveland Clinic, has received an "Intention to Grant" notice from the European Patent Office ("EPO") for the patent application titled "Ovarian Cancer Vaccines". The patent was invented by the late Dr. Vincent Tuohy, Dr. Suparna Mazumder, and Dr. Justin Johnson of Cleveland Clinic. Anixa exclusively licensed the technology from Cleveland Clinic and is developing the technology in partnership with the not-for-profit, multispecialty academic medical center.
The National Cancer Institute is collaborating on development through its PREVENT program. Anixa's ovarian cancer vaccine targets the extracellular domain of anti-Mullerian hormone receptor 2 (AMHR2-ED), which is expressed in the ovaries but disappears as a woman reaches and advances through menopause. However, AMHR2-ED is expressed again in the majority of ovarian cancers.
